KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

Acalabrutinib vs chlorambucil plus rituximab in untreated chronic lymphocytic leukemia: A randomized phase 3 Asian study.

Jia Li, Shuhua Yi, Thanh Nguyen, Wenjuan Yu, Keshu Zhou, Haiwen Huang, Udomsak Bunworasate, Man Huynh, Hui Zhou, Su-Peng Yeh, Yiqiu Wang, Xiaofeng Liu, Wei Fu, Lugui Qiu

Ann Hematol 105(8) 327

PMID42154070
PMCID-
DOI10.1007/s00277-026-07006-z
发表日期2026-05-19
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

Acalabrutinib is a selective, covalent Bruton tyrosine kinase inhibitor approved in multiple countries for patients with chronic lymphocytic leukemia (CLL). Acalabrutinib is approved in China for patients with CLL who received ≥ 1 prior therapy. We report results from a randomized, multicenter, open-label, phase 3 study (NCT04075292) evaluating the efficacy and safety of acalabrutinib vs chlorambucil plus rituximab (C + R) in medically unfit patients with treatment-naive CLL in Asia. As of January 3, 2024, 155 patients (overall cohort: acalabrutinib, n = 77; C + R, n = 78; China cohort [mainland China and Taiwan], n = 53 and n = 50, respectively) were enrolled. With a median follow-up of 23.5 and 18.2 months in the overall and China cohorts, respectively, acalabrutinib demonstrated a 92% risk reduction of disease progression or death vs C + R (both cohorts: hazard ratio, 0.08; P < 0.0001; primary endpoint). Overall response rates were 76.6% vs 71.8% with median duration of response not reached vs 11.6 months in the acalabrutinib vs C + R arms, respectively. In the acalabrutinib arm, no atrial fibrillation or hypertension events were observed. Efficacy and safety were consistent across cohorts. Acalabrutinib was well tolerated and demonstrated a progression-free survival benefit vs C + R in this Asian population.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。